ERBB2 and non-small cell lung carcinoma: The recent “basket” trial SUMMIT for patients with advanced solid tumors harboring ERBB2- or ERBB3-mutations exhibited a very low RR to neratinib in the included NSCLC cases (n = 26, all with ERBB2-mutations), with PR confined to one NSCLC with a missense mutation in ERBB2 TK domain, whereas no OR was seen in NSCLCs with ERBB2 exon 20 insertions [157].